Cambridge Investment Research Advisors Inc. Buys 756 Shares of iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA)

Cambridge Investment Research Advisors Inc. raised its stake in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) by 4.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 19,797 shares of the company’s stock after acquiring an additional 756 shares during the period. Cambridge Investment Research Advisors Inc. owned about 0.37% of iShares Genomics Immunology and Healthcare ETF worth $406,000 as of its most recent SEC filing.

Separately, Ameriprise Financial Inc. grew its position in iShares Genomics Immunology and Healthcare ETF by 23.6% in the fourth quarter. Ameriprise Financial Inc. now owns 71,832 shares of the company’s stock valued at $1,626,000 after acquiring an additional 13,721 shares during the period.

iShares Genomics Immunology and Healthcare ETF Price Performance

Shares of NYSEARCA:IDNA opened at $21.64 on Friday. The business’s fifty day moving average price is $20.49 and its two-hundred day moving average price is $21.24. iShares Genomics Immunology and Healthcare ETF has a fifty-two week low of $17.26 and a fifty-two week high of $25.80. The stock has a market capitalization of $111.45 million, a price-to-earnings ratio of 14.76 and a beta of 0.90.

iShares Genomics Immunology and Healthcare ETF Profile

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.